

Analytical BA/BE Case Study

Sarmistha Sanyal

Chemist,

Division of Generic Drug Study Integrity, Office of Study
Integrity and Surveillance, Office of Translational Sciences
CDER | US FDA

[CDER Inspections of Good Laboratory Practice, Animal Rule, and
Bioavailability/Bioequivalence Study Sites] – July 19, 2022



Disclaimer

- This presentation reflects the views of the author. It should not be construed to represent FDA's views or policies.



Learning Objectives

- Justifying rejection of an analytical run
 - Highlighting the importance of complete and contemporaneous documentation during an analytical BA/BE study
 - Maintaining analytical run data and audit trails
- * BA/BE – Bioavailability/Bioequivalence

Outline



- Analytical BA/BE Case Studies (1, 2 and 3)
- Questions/Discussions Relevant to Each Case Study



Case Study 1: Rejection of Analytical Run



Case Study 1:

- During method validation, one precision and accuracy (P&A) run was excluded from global P&A statistical analyses.
- Method validation report stated that the P&A run did not meet acceptance criteria since both HQC samples failed .
- This incident was documented and assessed as an assignable cause, but the assignable cause was not specified in the incident report.

Case Study 1: Continued

- During inspection, the firm management said they suspected that there were sample processing errors.
- Method validation SOP specifies that P&A batches, which do not meet acceptance criteria without an assignable cause should be included in global P&A calculations.

Examples of Assignable Cause



- Malfunction of HPLC or Spectrometric apparatus – can be mechanical or electrical in nature (pump stopped, leakage, power failure).
- Computer network issue – data not saved.
- Sample preparation error – if the nature of the error is known along with contemporaneous documentation.

Pause for Discussion: Case Study 1

Case Study 2: Complete and Contemporaneous Documentation

Case Study 2

- During an inspection, a firm could not provide quality control (QC) samples preparation documentation used in long-term stability studies for method validation experiments.
- As a result, long-term stability experiments could not be reconstructed.

Case Study 2 – Continued



- In another inspection, set of subject samples was classified as run failure. That set was reprocessed and reanalyzed.
- The firm stated that there was a suspected sample processing error.
- The firm could not provide supporting evidence for this incident to justify the reprocessing.

Pause for Discussion: Case Study 2

Case Study 3: Best Practices for Retaining Analytical Study Data

Case Study 3

During an inspection, following issues were observed while checking the audit trails of an analytical run:

- Changes to peak integration parameters was not uniformly applied
- Results table was overwritten; each version of the results table was not saved.
- Sample type was changed from 'quality control' to 'unknown' after analysis was completed.

Results Table – Sample Type	N/A	run03.wif, sample 35) was changed from “Quality Control” to “Unknown”
-----------------------------	-----	---

Pause for Discussion: Case Study 3

Summary



- 2018 Bioanalytical Method Validation Guidance should be viewed as recommendations while conducting an analytical BA/BE study.
- Any unexpected incidents, deviations from protocol or SOP, repeat analysis etc. should be supported by contemporaneous documentation.
- Rejecting a run or a sample should be justified and substantiated by proper documentation.
- Original and re-integrated results data should be maintained and supported by SOPs, protocols or other written documents.

Resources

Regulations

- ❑ [Regulation Part 320 – Bioavailability and Bioequivalence Requirements](#)

Related Guidance

- ❑ [Bioanalytical Method Validation \(BMV\) Guidance for Industry](#)
- ❑ [Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples](#)
- ❑ [FDA Guidance on Part 11, Electronic Records; Electronic Signatures](#)
- ❑ [Good Laboratory Practice for Nonclinical Laboratory Studies](#)
- ❑ [Regulatory Education for Industry: Regulated Bioanalysis Workshop: Requirements and Expectations](#)

Acknowledgement:

Dr. Seongeun (Julia) Cho

Dr. Stanley Au

Dr. Kara Scheibner

Dr. Melkamu Getie Kebtie

Thank You!

Sarmistha Sanyal

Chemist,

Division of Generic Drug Study Integrity, Office of Study Integrity and
Surveillance, Office of Translational Sciences

CDER | US FDA



U.S. FOOD & DRUG
ADMINISTRATION